Healthcare / Diagnostics & ResearchKOSDAQ
$2770.00
-20.00 (-0.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-20.3B · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$136.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-30.9%
↓Gross Margin
11.3%
↓Debt/Equity
0.51
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.0%
FCF CAGR
—
FCF margin
-69.0%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $29.36B · net income $-29.04B · FCF $-20.27B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $29.36B | $29.36B | $33.95B | $41.24B | $32.18B |
| Net Income | $-29.04B | $-29.04B | $-47.03B | $-27.48B | $-779.6M |
| EBITDA | $-27.47B | $-27.47B | $-49.34B | $-22.51B | $-44.8M |
| EPS | -587.00 | -587.00 | -1309.00 | -929.00 | -27.00 |
| Gross Margin | 11.3% | 11.3% | 15.1% | 18.4% | 31.3% |
| Operating Margin | -82.8% | -82.8% | -63.6% | -37.5% | 8.2% |
| Net Margin | -98.9% | -98.9% | -138.6% | -66.6% | -2.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.51 | 0.51 | 3.06 | 1.88 | 1.04 |
| Current Ratio | 13.46 | 13.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-20.27B | $-20.27B | $-20.86B | $-14.25B | $-873.0M |
| Returns | |||||
| ROE | -30.9% | -30.9% | -336.7% | -129.8% | -2.3% |
| Valuation | |||||
| P/B | 1.46 | 1.46 | 4.97 | 8.19 | 6.58 |
| Growth & Yield | |||||
| Revenue Growth | -13.5% | -13.5% | -17.7% | 28.1% | — |
| EPS Growth | 55.2% | 55.2% | -40.9% | -3340.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1309.00 → -587.00
Residual
+27.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.